Breaking News, Collaborations & Alliances

Synta, GSK End Pact

GSK returns rights to chemotherapy treatment elesclomol to Synta Pharma

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline and Synta Pharmaceuticals will end their collaborative agreement for the clinical development and commercialization of elesclomol, a chemotherapy adjuvant, by September 10, 2009. Worldwide rights to elesclomol will revert to Synta and Synta may pay GSK a low single-digit royalty on any potential future sales of elesclomol. “We appreciate GSK’s contributions to this program and understand their decision,” said Safi R. Bahcall, Ph.D., president and chief executive officer of Syn...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters